Seaport Therapeutics

gut epithelium
#Funding #Metabolic diseases #Pancreatic cancer #Seaport Therapeutics

$15m supports first oral therapy to restore gut lymphatic function

Seaport Therapeutics has received an award of up to $15 million to advance its GlyphCele, from the Advanced Research Projects Agency for Health (ARPA-H), in collaboration with the Monash Institute of Pharmaceutical Sciences (MIPS).  GlyphCele is an investigational Glyphed oral prodrug of the COX-2 inhibitor celecoxib, which is designed to… Read More

#Business & Investment #News

#Anxiety disorder #Neuropsychiatric disorders #Phase I trial #Seaport Therapeutics

First patient dosed in Seaport’s anxiety clinical trial

Biopharmaceutical company Seaport Therapeutics has announced that the first patient has been dosed in a Phase I clinical trial of its treatment for generalised anxiety disorder.   Seaport’s GlyphAgo is an oral prodrug of agomelatine, which is a clinically validated melatonin receptor agonist and serotonin 2C receptor antagonist. Read More

#News